ArticleTranslational oncology2026
Construction and validation of golgi apparatus-related genes as predictors of the immune microenvironment and prognosis in colorectal cancer.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is the third most common cancer globally, and the identification of novel biomarkers remains an urgent priority in clinical practice and research. Although the Golgi apparatus plays a crucial role in tumorigenesis and cancer progression, its role in CRC remains unclear.
methodsA comprehensive bioinformatics analysis of the transcriptome was conducted using the TCGA and GSE87211 datasets. A reliable risk signature model based on Golgi apparatus - related genes (GARGs) was constructed. Subsequently, we performed an in - depth single - cell RNA sequencing analysis. Finally, based on the consistent evidence across all analytical layers, GDI1 was selected for subsequent functional validation in cellular assays.
resultsBy integrating univariate Cox regression and LASSO analysis, we identified a five-GARG signature to construct a prognostic model. This model stratified patients into high- and low-risk groups with significantly different overall survival. The high-risk group was associated with elevated stromal and ESTIMATE scores, along with increased infiltration of monocytes and M0 macrophages, suggesting a potentially more immunosuppressive and tumor-promoting microenvironment. Bioinformatic predictions indicated that the high-risk group might show enhanced sensitivity to Dasatinib, Sapitinib, and SB216763; this was preliminarily supported by our subsequent in vitro drug sensitivity assays. Cell-cell communication analysis suggested that macrophages might primarily influence the microenvironment through the tumor necrosis factor (TNF) signaling pathway. Critically, functional experiments demonstrated that silencing GDI1 significantly inhibited cell proliferation and migration and induced apoptosis, supporting its potential oncogenic role in COAD.
conclusionCollectively, our work links GARG expression to CRC prognosis and immune features, and functionally implicates GDI1 in tumor cell aggressiveness, supporting its further study as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.